Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI -1.16%33 Pretax Margin % is % as of Mar. 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, GRI Bio ranks worse than 105708.14% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. GRI Bio's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-2.00 Mil. GRI Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, GRI Bio's pretax margin for the quarter that ended in Mar. 2026 was %.
The historical rank and industry rank for GRI Bio's Pretax Margin % or its related term are showing as below:
GRI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
GRI Bio Pretax Margin % Related Terms
GRI Bio Pretax Margin % Historical Data
* Premium members only.
The historical data trend for GRI Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI vs ISCO, VRAX, SLXN: Pretax Margin % Comparison
For the Biotechnology subindustry, GRI Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where GRI Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (GRI) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GRI Bio and its competitors. According to the industry distribution chart, GRI Bio ranks #999999 out of 946 companies in the Biotechnology industry.
Is GRI Bio's Pretax Margin % too high?
GRI Bio's current Pretax Margin % is %. Based on the distribution chart, GRI Bio ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's Pretax Margin % compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #999999 out of 946 companies for Pretax Margin %. This places GRI Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GRI Bio and its competitors. GRI Bio's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current Pretax Margin % of %. The current Pretax Margin % is %. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For GRI Bio (GRI), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score
Get the complete analysis for GRI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
